Clinico-pathologic Correlative Study of 3T Magnetic Resonance Spectroscopy in the Localization of Prostate Cancer
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- AHS Cancer Control Alberta
- Enrollment
- 16
- Locations
- 1
- Primary Endpoint
- characteristic metabolic pattern of prostate cancer at 3Tesla
Study Overview
Brief Summary
We seek to develop an advanced imaging approach to identifying and localizing prostate cancer. We believe that high field MRI (magnetic resonance imaging) has the potential to do this and we will endeavor to prove this by having patients with prostate cancer pre-operatively undergo a technique called magnetic resonance spectroscopy. After surgery, the microscopic locations of cancer will be compared with the pre-operative images to assess how well the imaging technique succeeds.
Detailed Description
The proposed research is enormously relevant to the clinical understanding of early prostate cancer. We propose to test to see whether characteristic patterns of invivo 3T MRSI associated metabolites can be identified in correlation with clinically active tumor reserved on histopathologic analysis of resected specimens. We also plan to demonstrate that 3T MR spectra of prostate cancer will allow for more detailed metabolic assessment with higher sensitivity, specificity and accuracy and publish results established from MR spectra using 1.5T MR units. Functional imaging (eg. molecular imaging such as this) is felt to be the clinical wave of the future for cancer imaging, and if successful, will assume a very major role in the detection, assessment, treatment planning and delivery of drugs, radiation, heat and novel therapeutics in the fight against prostate cancer.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Diagnostic
- Masking
- None
Eligibility Criteria
- Ages
- 40 Years to — (Adult, Older Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histologically verified prostate cancer
- •Patient has opted for surgery
- •Low risk prostate cancer PSA <1 0, Gleason < 7, Stage < T2b
- •No contraindication to MR scanning
- •No prior history of malignancy
- •Fit for surgery
Exclusion Criteria
- •Nonbiopsied lesion
- •Intermediate or high risk prostate cancer
- •Unfit for surgery
- •Contraindication to MR scanning (i.e. pacemaker, aneurysm clips, claustrophobia)
Outcomes
Primary Outcomes
characteristic metabolic pattern of prostate cancer at 3Tesla
Secondary Outcomes
- PPV of MRS in the detection of prostate cancer
- specificity, accuracy, NPV